Archive

8 Feb 2016

The Centre for Therapeutic Target Validation welcomes new member Biogen, expanding its efforts to accelerate drug discovery research

Biogen has joined the Centre for Therapeutic Target Validation (CTTV), the pioneering public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GSK, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters interactions between academic and industry members to select and validate novel targets in drug development.

19 Jan 2016

DNA from ancient British skeletons reveals immigrant history

For the first time, researchers have been able to directly estimate the Anglo-Saxon ancestry of the British population from ancient skeletons, showing how Anglo-Saxon immigrants mixed with the native population

11 Jan 2016

New protocol allows links between DNA methylation and gene expression to be studied in the same cells

A new single-cell genomics method to study links between DNA modifications (methylation) and the activity of a gene has been developed. This is the first method that allows scientists to study the epigenome and transcriptome of a single cell in parallel, helping researchers pinpoint the relationship between changes in DNA methylation and gene expression. 

18 Dec 2015

Cichlid fish from a tiny volcanic crater have been caught in the act of sympatric speciation

Can new species really evolve if there is no physical boundary to drive genetic separation? Physical and genomic evidence from the 700-metre wide volcanic crater Lake Massoko appears to have caught the process in the act

14 Dec 2015

Risk of having two children with the same genetic disorder is determined by mutation timing

Researchers compared mutation rates in sperm and eggs for multi-sibling families, confirming that fathers contribute more mutations to their children than mothers. They revealed for the first time that the rate at which mutations in sperm accumulate with age varies from father to father.

11 Dec 2015

New tool helps to visualise, understand and predict how proteins combine to drive biological processes

A new ‘periodic table’ of protein complexes has been developed that provides a unified way to classify and visualise protein complexes, providing a valuable tool for biotechnology and the engineering of novel complexes. This study also provides insights into evolutionary distribution of different types of existing protein complexes.

8 Dec 2015

A web interface to help researchers find therapeutic targets for new and repurposed medicines is launched by the Centre for Therapeutic Target Validation (CTTV)

Establishing the validity of an association between a disease and biological target for a drug can be extremely challenging and expensive. To address this challenge, the CTTV, a collaboration between GSK, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), has created a web-based platform (www.targetvalidation.org) that draws on public data resources to help drug discovery. This state-of-the-art web interface will allow researchers to access thousands of target profiles summarising the evidence for the involvement of a specific gene product with a disease.

7 Dec 2015

Movies of cell growth explain skin graft success and may help understand cancer

Sanger Institute scientists have found that all dividing skin cells can flip between two probability game modes and so have the potential to both maintain and heal skin, challenging the view that only rare stem cells matter. Understanding the rules of the games not only explains how skin maintains itself and heals wounds, but also shows how skin grafts work and suggests how changes to the rules could lead to cancer.

9 Nov 2015

Cancer and ageing could be predetermined by the speed of molecular clocks

A theory that our cells have molecular clock processes ticking inside them, that damage DNA by generating mutations continuously throughout life, has just been proven. These clock-like mutational processes could ultimately be responsible for a large proportion of human cancer and contribute to human ageing. Two clock-like mutational processes have been found in human cells and the rates at which the two clocks tick in different human cell types have been determined.

29 Oct 2015

Genomic fingerprint can highlight which breast, ovarian, pancreatic and gastric cancers are likely to respond to treatment

Gastric cancer, otherwise known as stomach cancer, does not respond well to existing treatments and it is currently the third leading cause of cancer death in the world (after lung and liver cancer). Researchers have discovered that certain drugs, currently used to treat breast, ovarian and pancreatic cancers, could also be used to treat certain gastric cancers with a particular pattern of mutations (genomic molecular fingerprint).

Pages